Skip to content

Royal Jelly in acute leukemia

Evaluation of the effectiveness and safety of Royal Jelly on the number of white blood cells in patients with acute lymphoblastic leukemia

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190106042260N1
Enrollment
20
Registered
2020-05-26
Start date
2020-02-20
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic lymphoma ( ALL ). Acute lymphoblastic leukemia [ALL]

Interventions

Intervention group: Children with acute lymphoblastic lymphoma ( before entering the study and using a jelly)? The gel used is Royal Jelly, which is a honey product that is completely natural and has

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Patients with acute lymphoblastic leukemia who are in the complete maintenance and remission phase. Having a normal heart echo No history of asthma No history of allergy to honey and its products

Exclusion criteria

Exclusion criteria: history of allergy to honey and its products history of asthma Cardiomyopathy and underlying heart problem

Design outcomes

Primary

MeasureTime frame
Total ?White blood cell count. Timepoint: from beginning ( before using a Jelly ), then every two week until 6 weeks. Method of measurement: Complete blood count (CBC).;Acute lymphocyte count. Timepoint: from beginning ( before using a Jelly ), then every two week until 6 weeks. Method of measurement: Complete blood count (CBC) /Differential Cell Exam.;Acute Neutrophil count. Timepoint: from beginning ( before using a Jelly ), then every two week until 6 weeks. Method of measurement: Complete blood count (CBC) /differential cell exam.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRozhin Pahlevani

Iran University of Medical Sciences

Pahlevan.r@iums.ac.ir+98 21 4431 9829

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026